Myriad Genetics, Inc. Forecast, price target & analysts
Myriad Genetics, Inc. Target price 2025 - Analyst rating & recommendation
Myriad Genetics, Inc. Classifications & Recommendation:
Myriad Genetics, Inc. Price Target
| Target Price | $17.33 |
| Price | $11.06 |
| Potential |
56.72%
register free of charge
|
| Number of Estimates | 15 |
|
15 Analysts have issued a price target Myriad Genetics, Inc. 2026 .
The average Myriad Genetics, Inc. target price is $17.33.
This is
56.72%
register free of charge
$29.00
162.21%
register free of charge
$8.00
27.67%
register free of charge
|
|
| A rating was issued by 15 analysts: 6 Analysts recommend Myriad Genetics, Inc. to buy, 5 to hold and 4 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Myriad Genetics, Inc. stock has an average upside potential 2026 of
56.72%
register free of charge
|
Sales and Margin forecast 2025, 2026 to 2029
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Million $ | 837.60 | 848.73 |
| 11.21% | 1.33% | |
| EBITDA Margin | -3.41% | 2.53% |
| 63.98% | 174.10% | |
| Net Margin | -15.37% | -6.40% |
| 60.13% | 58.36% |
15 Analysts have issued a sales forecast Myriad Genetics, Inc. 2025 . The average Myriad Genetics, Inc. sales estimate is
This results in the following potential growth metrics:
11 Analysts have issued an Myriad Genetics, Inc. EBITDA forecast 2025. The average Myriad Genetics, Inc. EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
10 Myriad Genetics, Inc. Analysts have issued a net profit forecast 2025. The average Myriad Genetics, Inc. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2029
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -1.41 | -0.60 |
| 55.66% | 57.45% | |
| P/E | negative | |
| EV/Sales | 1.23 |
10 Analysts have issued a Myriad Genetics, Inc. forecast for earnings per share. The average Myriad Genetics, Inc. <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is
This results in the following potential growth metrics and future valuations:
Based on analysts' sales estimates for 2025, the Myriad Genetics, Inc. stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of
This results in the following potential growth metrics and future valuations:
Myriad Genetics, Inc....
Current Myriad Genetics, Inc. Upgrades & Downgrades Beta
| Analyst | Rating | Action | Date |
|---|---|---|---|
| UBS | Locked ➜ Locked | Locked | Feb 25 2025 |
| Raymond James | Locked ➜ Locked | Locked | Feb 25 2025 |
| Craig-Hallum | Locked ➜ Locked | Locked | Feb 12 2025 |
| Piper Sandler | Locked ➜ Locked | Locked | Jan 30 2025 |
| Goldman Sachs | Locked ➜ Locked | Locked | Jan 28 2025 |
| Stephens & Co. | Locked ➜ Locked | Locked | Jan 16 2025 |
| B of A Securities | Locked ➜ Locked | Locked | Dec 13 2024 |
| Analyst Rating | Date |
|---|---|
|
Locked
UBS: Locked ➜ Locked
|
Feb 25 2025 |
|
Locked
Raymond James: Locked ➜ Locked
|
Feb 25 2025 |
|
Locked
Craig-Hallum: Locked ➜ Locked
|
Feb 12 2025 |
|
Locked
Piper Sandler: Locked ➜ Locked
|
Jan 30 2025 |
|
Locked
Goldman Sachs: Locked ➜ Locked
|
Jan 28 2025 |
|
Locked
Stephens & Co.: Locked ➜ Locked
|
Jan 16 2025 |
|
Locked
B of A Securities: Locked ➜ Locked
|
Dec 13 2024 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
